REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells

Cell Cycle

Volumn 8, Issue 5, 2009, Pages 780-786

  Chang, Bin ^a,b,c   Liu, Guangzhi ^a   Yang, Gong ^a   Mercado Uribe, Imelda ^a   Huang, Miao ^a   Liu, Jinsong ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SHIHEZI UNIVERSITY   (China)

Author keywords

Anti apoptosis; Ovarian cancer; RAS; REDD1; Transformation

Indexed keywords

CASPASE 10; CASPASE 8; CASPASE 9; FAS ASSOCIATED DEATH DOMAIN PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; RAS PROTEIN;

APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CELL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REDD1 GENE; TUMOR GROWTH;

MUS MUSCULUS;

EID: 62449242845     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.5.7887     Document Type: Article

References (24)

1. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002; 22:2283-93.
2. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002; 10:995-1005.
3. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004; 18:2893-904.
4. Lin L, Stringfield TM, Shi X, Chen Y. Arsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors Elk-1 and CCAAT/enhancer-binding protein. Biochem J 2005; 392:93-102.
5. Tang Y, Pacary E, Freret T, Divoux D, Petit E, Schumann-Bard P, et al. Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: identification of potential neuroprotective candidates for stroke. Neurobiol Dis 2006; 21:18-28.
6. Kim JR, Lee SR, Chung HJ, Kim S, Baek SH, Kim JH, et al. Identification of amyloid beta-peptide responsive genes by cDNA microarray technology: involvement of RTP801 in amyloid beta-peptide toxicity. Exp Mol Med 2003; 35:403-11.
7. Brafman A, Mett I, Shafir M, Gottlieb H, Damari G, Gozlan-Kelner S, et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci 2004; 45:3796-805.
8. Lang CH, Frost RA, Vary TC. Acute alcohol intoxication increases REDD1 in skeletal muscle. Alcohol Clin Exp Res 2008; 32:796-805.
9. Adelman DM, Maltepe E, Simon MC. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev 1999; 13:2478-83.
10. Scheid A, Wenger RH, Christina H, Camenisch I, Ferenc A, Stauffer UG, et al. Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair. Pediatr Surg Int 2000; 16:232-6.
11. Semenza GL, Agani F, Feldser D, Iyer N, Kotch L, Laughner E, et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol 2000; 475:123-30.
12. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 2008; 22:239-51.
13. Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, Kaufmann J. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 2005; 24:1138-49.
14. Cao L, Xu X, Cao LL, Wang RH, Coumoul X, Kim SS, et al. Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach. Carcinogenesis 2007; 28:1401-7.
15. An SJ, Chen JK, Liu LL, Zhao YF, Chen XM. Overexpressed genes detected by suppression subtractive hybridization in carcinoma derived from transformed 16HBE cells induced by BPDE. Biomed Environ Sci 2005; 18:302-6.
16. Thullberg M, Stromblad S. Anchorage-independent cytokinesis as part of oncogenic transformation? Cell Cycle 2008; 7:984-8.
17. Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53:1489-92.
18. Ichikawa Y, Nishida M, Suzuki H, Yoshida S, Tsunoda H, Kubo T, et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994; 54:33-5.
19. Fujita M, Enomoto T, Inoue M, Tanizawa O, Ozaki M, Rice JM, et al. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 1994; 85:1247-56.
20. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997; 79:1581-6.
21. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Prat J. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer 1998; 82:1088-95.
22. Varras MN, Sourvinos G, Diakomanolis E, Koumantakis E, Flouris GA, Lekka-Katsouli J, et al. Detection and clinical correlations of ras gene mutations in human ovarian tumors. Oncology 1999; 56:89-96.
23. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004; 64:1655-63.
24. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene 2003; 22:5694-701.